Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients.

ABSTRACT: We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered early, sotrovimab is effective at preventing coronavirus disease 2019 progression in immunocompromised and nonimmunocompromised patients.

SUBMITTER: Birk NK 

PROVIDER: S-EPMC9214182 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature